Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Susan Walisser"'
Autor:
Randeep Sangha, Jaya Venkatesh, Daniel T. Grima, William K. Evans, Parneet K. Cheema, D. Tran, Susan Walisser, D. Moldaver, Barbara Melosky, Erik Orava, M. Hurry, Darryl Boehm, Ronald Burkes
Publikováno v:
Lung Cancer. 151:110-111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c2735d3b4d7cdfa0a820f429636ded
https://doi.org/10.1016/j.lungcan.2020.11.015
https://doi.org/10.1016/j.lungcan.2020.11.015
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:33-36
Background Bevacizumab is an antiangiogenic agent active in patients with recurrent malignant gliomas. However, evidence for its clinical efficacy is relatively limited so that bevacizumab is approved for this indication in Canada and the United Stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95435aeec390596a818b0b448b599c33
https://doi.org/10.1177/1078155216681191
https://doi.org/10.1177/1078155216681191
Publikováno v:
Journal of Oncology Pharmacy Practice. 23:284-287
Background Patient adherence is important with the increasing use of oral anticancer drugs. Recent studies reported different capecitabine adherence rates based on self-reporting and microelectronic monitoring of the medication bottle. Patient’s aw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0d69409d2827421f91d0125b2d33d34
https://doi.org/10.1177/1078155216676631
https://doi.org/10.1177/1078155216676631
Autor:
Elizabeth, Borycki, Jeff, Barnett, Susan, Walisser, Paule, Bellwood, Melissa, Clarke, David, Greig
Publikováno v:
Studies in health technology and informatics. 180
Adverse drug events are a significant global health issue. In this paper we describe our research work to date in identifying the characteristics of patients who are at risk for adverse drug events. We conducted a focus group study with health profes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa311bac33d205498295047f51d0fd0a
https://pubmed.ncbi.nlm.nih.gov/22874198
https://pubmed.ncbi.nlm.nih.gov/22874198
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 18(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca67d2cb91f11e84a32eb66006f53fa
https://pubmed.ncbi.nlm.nih.gov/22573212
https://pubmed.ncbi.nlm.nih.gov/22573212
Publikováno v:
Journal of Clinical Oncology. 33:e13021-e13021
e13021 Background: Health Canada approved the use of Bevacizumab (Bev) in recurrent gliomas in Mar 2010. However, there is limited evidence for its use for this indication. In Canada, several provi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ee7f5de5209772cc752099bd697f518
https://doi.org/10.1200/jco.2015.33.15_suppl.e13021
https://doi.org/10.1200/jco.2015.33.15_suppl.e13021
Autor:
Mário L de Lemos, Susan Walisser
Publikováno v:
Journal of Oncology Pharmacy Practice. 11:159-160
Oxaliplatin extravasation has been associated with local pain and inflammation which may be severe and lead to complications including necrosis. Recent case reports suggest that oxaliplatin may be better classified as an irritant when extrava-sated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0def27012d972e91d57b6145e384f46c
https://doi.org/10.1191/1078155205jp165oa
https://doi.org/10.1191/1078155205jp165oa